Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Under-reporting of adverse effects of tesofensine.

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM.

Lancet. 2013 Jul 13;382(9887):127. doi: 10.1016/S0140-6736(13)61563-9. No abstract available.

PMID:
23849924
2.

Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

[No authors listed]

Lancet. 2013 Apr 6;381(9873):1167. doi: 10.1016/S0140-6736(13)60778-3. No abstract available.

PMID:
23561987
3.

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM.

Lancet. 2008 Nov 29;372(9653):1906-13. doi: 10.1016/S0140-6736(08)61525-1. Epub 2008 Oct 22.

PMID:
18950853
5.

[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].

Nielsen AL, Larsen TM, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Astrup A.

Ugeskr Laeger. 2009 Oct 5;171(41):2974-7. Danish.

PMID:
19824222
6.

Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.

Bello NT, Zahner MR.

Curr Opin Investig Drugs. 2009 Oct;10(10):1105-16. Review.

PMID:
19777399
7.

Tesofensine and weight loss.

Sommet A, Pathak A, Montastruc JL.

Lancet. 2009 Feb 28;373(9665):719; author reply 720. doi: 10.1016/S0140-6736(09)60433-5. No abstract available.

PMID:
19249626
8.

Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats.

van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J.

Eur Neuropsychopharmacol. 2012 Apr;22(4):290-9. doi: 10.1016/j.euroneuro.2011.07.015. Epub 2011 Sep 1.

PMID:
21889317
9.
10.

Is new hope on the horizon for obesity?

Bray GA.

Lancet. 2008 Nov 29;372(9653):1859-60. doi: 10.1016/S0140-6736(08)61792-4. No abstract available.

PMID:
19041787
11.

The effect of tesofensine on appetite sensations.

Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjödin A.

Obesity (Silver Spring). 2012 Mar;20(3):553-61. doi: 10.1038/oby.2011.197. Epub 2011 Jun 30.

12.

Tesofensine and weight loss.

Tsai AG.

Lancet. 2009 Feb 28;373(9665):719; author reply 720. doi: 10.1016/S0140-6736(09)60432-3. No abstract available.

PMID:
19249625
13.

The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.

Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, Mikkelsen JD.

Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95. doi: 10.1016/j.ejphar.2010.03.026. Epub 2010 Apr 10.

PMID:
20385125
14.

Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.

Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH.

Obesity (Silver Spring). 2013 May;21(5):985-92. doi: 10.1002/oby.20122.

15.

Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.

Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM.

Obesity (Silver Spring). 2008 Jun;16(6):1363-9. doi: 10.1038/oby.2008.56. Epub 2008 Mar 20.

16.

Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat.

Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD.

Pharmacol Biochem Behav. 2013 Sep;110:265-71. doi: 10.1016/j.pbb.2013.07.018. Epub 2013 Aug 7.

PMID:
23932919
17.

Serotonergic anti-obesity agents: past experience and future prospects.

Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA.

Drugs. 2011 Dec 3;71(17):2247-55. doi: 10.2165/11596680-000000000-00000. Review.

PMID:
22085383
18.

[Is there a future for medical treatment of obesity?].

Richelsen B.

Ugeskr Laeger. 2009 Oct 5;171(41):2973. Danish. No abstract available.

PMID:
19814923
19.

The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A.

Int J Obes (Lond). 2010 Nov;34(11):1634-43. doi: 10.1038/ijo.2010.87. Epub 2010 May 18.

PMID:
20479765
20.

Comparative efficiency and safety of pharmacological approaches to the management of obesity.

Hainer V.

Diabetes Care. 2011 May;34 Suppl 2:S349-54. doi: 10.2337/dc11-s255. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk